Breast Cancer Prevention Study: Are Healthy Women Put at Risk by Federally Funded Research? : Hearing Before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred Second Congress, Second Session, October 22, 1992
United States. Congress. House. Committee on Government Operations. Human Resources and Intergovernmental Relations Subcommittee
U.S. Government Printing Office, 1994 - Breast - 272 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
adjuvant adjuvant tamoxifen BCPT bone bone fractures Breast Cancer Action breast cancer prevention breast tumors Cancer Prevention Trial cardiovascular centers Chairman chemoprevention cholesterol clinical trials concern contralateral breast developing breast cancer Director disease dose effects of tamoxifen eligible endometrial cancer estrogen Evaluation evidence exam follow-up Food and Drug GREENWALD Gregory Burke healthy women HEALY high risk hormone human increased risk informed consent informed consent form liver cancer menopausal minority women model informed consent National Cancer Institute National Surgical Adjuvant Oncology osteoporosis Participant's participate patients PAYNE percent physician placebo population postmenopausal postmenopausal women premenopausal women prevent breast cancer problems public health questions rats receiving tamoxifen recruitment reduce reported risk of breast risk of developing risks and benefits says side effects subcommittee subjects taking tamoxifen tamoxifen study tamoxifen therapy tamoxifen trial tests tion toxicity treatment uterine cancer woman Women's Health